Scholars Central

Research articlePublished 19 Nov 2021

Does add on therapy of Fenofibrate to Statins prevent the glycemic effect of statins and new-onset diabetes?

Authors: Jameel Ahmed

Clinical Pharmacology and Toxicology Research

Volume 4 · Issue 6 · Pages 1–4

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Cardiovascular disease (CVD) remains the leading cause of death worldwide as per the WHO, and it still confers a large economic burden on society. Multiple risk factors have been identified for developing coronary heart disease (CHD). The most understood and discussed risk factors among them are dyslipidemia and diabetes mellitus1. Lipid lowering therapies have been shown to lower the risk of CHD events by 30-40%2. Randomized statin trials have shown that a reduction in LDL-C by 80 mg/dl results in a decrease of coronary artery disease (CAD) by 42% and stroke by 20%. 3 Drugs that are generally used to treat dyslipidemia include fibric acid derivatives, ezetimibe and statins etc. The statins currently forming the mainstay of hypolipidemic drugs have proven mortality and morbidity benefit in both primary and secondary prevention of CHD 4,5 Diabetes is another risk factor commonly recognized as a “coronary heart disease risk equivalent” 6,7. Type 2 diabetes mellitus (T2DM) mostly results from the interaction among genetic, environmental and other risk factors but certain drugs (e.g. glucocorticoids, β-adrenergic agonists and thiazides etc.) may also precipitate diabetes in individuals with insulin resistance.8 On February 28, 2012, the Food and Drug Administration (FDA) added new safety label changes for using the statins because of their potential to increase HbA1c. Recently, an Intervention Trial Evaluating Rosuvastatin (JUPITER) a placebo controlled, primary prevention trial reported a 26% higher incidence of diabetes in the Rosuvastatin Group at1.9 years interim analysis. 9 WHI (Women's Health Initiative) study also suggested an increased risk of New Onset Diabetes Mellitus (NODM) with different statins.10 A metaanalysis of diabetics found that a 1%point increase in HbA1c level confers an 18% risk of CVD .11 worldwide as per the WHO, and it still confers a large economic burden on society. Multiple risk factors have been identified for developing coronary heart disease (CHD). The most understood and discussed risk factors among them are dyslipidemia and diabetes mellitus1. Lipid lowering therapies have been shown to lower the risk of CHD events by 30-40%2. Randomized statin trials have shown that a reduction in LDL-C by 80 mg/dl results in a decrease of coronary artery disease (CAD) by 42% and stroke by 20%. 3 Drugs that are generally used to treat dyslipidemia include fibric acid derivatives, ezetimibe and statins etc. The statins currently forming the mainstay of hypolipidemic drugs have proven mortality and morbidity benefit in both primary and secondary prevention of CHD 4,5 Diabetes is another risk factor commonly recognized as a “coronary heart disease risk equivalent” 6,7. Type 2 diabetes mellitus (T2DM) mostly results from the interaction among genetic, environmental and other risk factors but certain drugs (e.g. glucocorticoids, β-adrenergic agonists and thiazides etc.) may also precipitate diabetes in individuals with insulin resistance.8 On February 28, 2012, the Food and Drug Administration (FDA) added new safety label changes for using the statins because of their potential to increase HbA1c. Recently, an Intervention Trial Evaluating Rosuvastatin (JUPITER) a placebo controlled, primary prevention trial reported a 26% higher incidence of diabetes in the Rosuvastatin Group at1.9 years interim analysis. 9 WHI (Women's Health Initiative) study also suggested an increased risk of New Onset Diabetes Mellitus (NODM) with different statins.10 A metaanalysis of diabetics found that a 1%point increase in HbA1c level confers an 18% risk of CVD .11

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Clinical Pharmacology and Toxicology Research.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalClinical Pharmacology and Toxicology Research
  • SubjectPharmaceutical Sciences
  • SubjectToxicology
  • BylineArticles whose byline prints “Jameel Ahmed”